Table 1.
Distant metastasis-free survival Cox proportional hazards models of primary breast cancer patients
| Variables | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| HR | Lower 95 % | Upper 95 % | p Value | HR | Lower 95 % | Upper 95 % | p Value | |
| Age (cont. variable) | 0.989 | 0.983 | 0.996 | 0.003 | 0.996 | 0.988 | 1.003 | 0.257 |
| Node status | 1.176 | 0.851 | 0.992 | 0.063 | 1.695 | 1.315 | 2.184 | <0.001 |
| Tumor size T2–T4 versus T0–T1 | 1.305 | 1.104 | 1.541 | 0.002 | 1.242 | 1.042 | 1.480 | 0.015 |
| Treatment (yes vs. no) | 0.973 | 0.845 | 1.121 | 0.707 | 0.547 | 0.428 | 0.700 | <0.001 |
| PAM50 | ||||||||
| Luminal A | 1.0 | – | – | – | 1.0 | – | – | – |
| Luminal B | 1.797 | 1.503 | 2.149 | <0.001 | 2.041 | 1.578 | 2.641 | <0.001 |
| HER2-E | 2.677 | 2.120 | 3.380 | <0.001 | 1.648 | 1.073 | 2.530 | 0.023 |
| Basal-like | 2.144 | 1.737 | 2.647 | <0.001 | 1.312 | 0.812 | 2.121 | 0.268 |
| Normal-like | 1.073 | 0.670 | 1.718 | 0.769 | 1.024 | 0.572 | 1.835 | 0.936 |
| Three-gene signature | ||||||||
| ER+/HER2−/Low Prolif | 1.0 | – | – | – | 1.0 | – | – | – |
| ER+/HER2−/High Prolif | 1.852 | 1.531 | 2.241 | <0.001 | 1.153 | 0.882 | 1.508 | 0.297 |
| HER2+ | 2.785 | 2.196 | 3.533 | <0.001 | 1.588 | 1.053 | 2.395 | 0.028 |
| ER−/HER2− | 2.536 | 2.041 | 3.150 | <0.001 | 1.762 | 1.095 | 2.835 | 0.020 |
HER2-E HER2-enriched, Prolif proliferation, HR hazard ratio